Table 1.
Baseline Demographic and Clinical Characteristic by Study Arm
| Characteristic | Total (n=48) | Arm A (n=24) | Arm B (n=24) | p-value |
|---|---|---|---|---|
| Vaccine | Vaccine plus GM-CSF |
|||
| Median age (IQR) | 41 (33–50) | 40 (29–50) | 41 (35–47) | 0.79a |
| Male gender | 38 (79%) | 18 (75%) | 20 (83%) | 0.72b |
| Race/ethnicity | ||||
| White | 26 (54%) | 10 (42%) | 16 (67%) | 0.23b |
| Black | 15 (31%) | 10 (42%) | 5 (21%) | |
| Hispanic | 7 (15%) | 4 (17%) | 3 (13%) | |
| IVDU | 2 (4%) | 0 (0%) | 2 (8%) | 0.49b |
| Median CD4 cell count (IQR) | ||||
| Week 0 | 445 (273–569) | 461 (307–631) | 445 (271–536) | 0.41a |
| Nadir | 157 (55–343) | 179 (54–337) | 157 (71–343) | 0.99a |
| On HAART at week 0 | 37 (77%) | 19 (79%) | 18 (75%) | 1.00b |
| Week 0 HIV RNA | ||||
| Median log10 (IQR) | 1.74 (1.70–2.55) | 1.73 (1.70–2.39) | 1.76 (1.70–2.57) | 0.70a |
| <1000 cp/mLc | 39 (81%) | 20 (83%) | 19 (79%) | 1.00b |
| <50 cp/mL | 26 (54%) | 13 (54%) | 13(54%) | 1.00b |
Column percentages presented.
a
Wilcoxon Rank Sum Test.
b
Fisher’s Exact Test.
c
Study stratification factor.